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Abstract
Introduction: Anti-cholinergic medications have been associated with increased risks of cognitive impairment,
premature mortality and increased risk of hospitalisation. Anti-cholinergic load associated with medication
increases as death approaches in those with advanced cancer, yet little is known about associated adverse
outcomes in this setting.
Methods: A substudy of 112 participants in a randomised control trial who had cancer and an Australia
modified Karnofsky Performance Scale (AKPS) score (AKPS) of 60 or above, explored survival and health service
utilisation; with anti-cholinergic load calculated using the Clinician Rated Anti-cholinergic Scale (modified
version) longitudinally to death. A standardised starting point for prospectively calculating survival was an
AKPS of 60 or above.
Results: Baseline entry to the sub-study was a mean 62 81 days (median 37, range 1–588) days before death
(survival), with mean of 4.8 (median 3, SD 4.18, range 1 – 24) study assessments in this time period. Participants
spent 22% of time as an inpatient. There was no significant association between anti-cholinergic score and time
spent as an inpatient (adjusted for survival time) (p¼ 0.94); or survival time.
Discussion: No association between anti-cholinergic load and survival or time spent as an inpatient was seen.
Future studies need to include cognitively impaired populations where the risks of symptomatic deterioration
may be more substantial.
Introduction
Medications with cholinergic effects have been as-sociated with significant morbidity including un-
pleasant symptoms, accelerated functional decline, delirium
(and its associated poor outcomes), cognitive impairment and
risk of drug interactions.1–9 Little is known about the impact
of prescribing anti-cholinergic medications on outcomes per-
tinent to palliative care for people with advanced cancer.
Anti-cholinergic load associatedwith medications has been
documented to increase as death approaches, mainly from the
addition of symptom control medications.7 This is in the
context of an average of five or more medications per person
in people with advanced disease, both for symptom control
and for comorbid conditions.10,11 In those with advancing
cancer, it is also postulated that specific tumour-derived fac-
tors, cytokines, and other endogenous substances may have
anti-cholinergic activity, and therefore also add to anti-
cholinergic burden.12,13 There are similar processes in acute
illnesses that generate a significant cytokine response.
The adverse effects of anti-cholinergic medication such as
dry mouth, dizziness, acute cognitive impairment and con-
stipation can iatrogenically increase symptom burden, which
is especially problematic in people with advancing cancer
when symptom burden is already high.6–8 In a prior study in a
larger palliative care population derived from the same ran-
domised controlled trial (RCT), total anti-cholinergic loadwas
significantly associated with lower levels of global function,
difficulty concentrating and dry mouth.7
Many symptom-specific medications meet also Beers’
criteria as high risk medications in older adults, and are
associated with additional adverse effects from drug-drug
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interactions (in particular in the elderly, those with multiple
comorbidities, and in particular tumour types e.g., brain tu-
mours).10,14 Medications that are ‘‘high risk’’ on Beers’ criteria
can lead to increased risks of hospitalization and premature
mortality.15–17
To date there has been no study of people with advanced
cancer exploring the association between anti-cholinergic
medication burden and health service utilisation or survival
outcomes.15–17 The aim of this sub-study was to explore as-
sociations of anti-cholinergic load in people with advanced
cancer on health service utilisation and survival. The null
hypotheses were that anti-cholinergic load was not associated
with increased health service utilisation nor decreased sur-
vival in people with advanced cancer.
Methods
Setting
Southern Adelaide Palliative Services is a specialist met-
ropolitan palliative care programme, which provides inpa-
tient care, community and outpatient visits, nursing home
and hospital consultations, and also offers volunteer, com-
plementary care and bereavement services. It serves a popu-
lation of 350,000 people over an area of more than 750 km2
providing services in both the public and private sectors.
Palliative Care Unit inpatients receive direct clinical care,
while all other care is in conjunction with the person’s prin-
cipal clinical team or their general practitioner and commu-
nity nursing services. The Australian healthcare system
provides universal insurance that can be supplemented by
private insurance and co-payments for many community
services.
Study design
This sub-study is a secondary analysis of participants in the
Palliative Care Trial (PCT). The PCTwas a prospective 222
factorial unblinded cluster RCT of educational outreach vis-
iting and case conferencing in people with advanced disease.
The full clinical trial methodology has been detailed else-
where.18,19 The PCT enrolled 461 consenting participants and
their general practitioners between April 2002 and June 2004.
The inclusion criteria were patients with any form of pain in
the three months preceding assessment. Exclusion criteria
included: place of residence outside the geographic area,
death expected within 48 hours of referral, and Folstein Mini-
Mental Status Examination (MMSE)20 score 24 at baseline
assessment, unless there was a suitable proxy who could
provide consent.
Ethics approval
This trial was approved by all twelve relevant independent
HRECs and IRBs including the Australian Department of
Veteran Affairs andHealth Insurance Commission, Canberra,
Australia. The trial is registered with the ISRCTN81117481
(http://www.controlled–trials.com/isrctn/trials/81117481/
0/81117481.html).
Participants for secondary analysis
The inclusion criteria for the secondary analysis were:
1. a diagnosis of cancer;
2. known date of death;
3. Australia – modified Karnofsky Performance Scale
(AKPS) score at initial assessment of 60 or above; and
4. AKPS score fell to below 60 at some time point during
longitudinal follow-up.
The Australia–modified Karnofsky Performance Scale
(AKPS) is a functional scale where 100 equates with full
function, a score less than 70 requires increasing support from
other people, less than 30 is totally dependent on others’ help,
and 0 is dead.21 In order to standardise a common starting
point for the calculation of survival in this population, only
people whose Karnofsky score was 60 or above at initial as-
sessment were included in the analyses. The baseline time
point was defined as the first visit at which AKPS score was
below 60. This gave a homogenous starting point from pro-
spectively collected data for the subsequent health service
utilisation and survival trajectories to be considered given the
widely varying time-points at which referral to specialist
palliative care services can occur before death.
Assessments
All participants enrolled in the PCT trial underwent
community-based reviews at initial referral, fortnightly for 3
months, and then at least monthly until death. A list of regular
medications was recorded at each visit (generic drug name,
dose, route of administration, indication, frequency and pat-
tern of use). Data excluded medications used on an as-needed
basis, short coursemedications such as antibiotics, intravenous
chemotherapy, and agents with no Australian Therapeutics
Code (complementary or alternative therapies), given the lat-
ter’s wide variation in labelling and poorly characterised anti-
cholinergic loads.10
Data collection
Baseline assessments included demographic data (age,
gender, primary diagnosis, co-morbid diseases, and date of
referral to the service). At each visit the presence or absence of
symptoms including dry mouth, constipation, hallucinations
and confusion was recorded using clinical assessment and the
Memorial Symptom Assessment Scale.22 Functional assess-
ment was made at each review using the AKPS. Quality of
life was measured at each visit using the McGill Quality of
Life Scale.23
Calculation of total anti-cholinergic score,
survival, and health service utilisation
The Clinician Rated Anti-cholinergic Scale (modified ver-
sion) was used.24,25 Each medication is rated from 0 (no
known anti-cholinergic effect) to 3 (marked anti-cholinergic
effects).24,25 Total anti-cholinergic score (baseline) was cal-
culated as the sum of anti-cholinergic scores for each medi-
cation being received regularly at the baseline time-point.
For purpose of analysis total anti-cholinergic score at baseline
was divided into three strata from summed scores with ap-
proximately equal numbers of patients: 0–2, 3–5, and 6–9.
The three strata of anti-cholinergic scores were entered
into models as categorical variables. Survival was calculated
as the number of weeks from the baseline time point (crossing
AKPS score of 60 as functional decline occurred) until death.
Health service utilisation was obtained by summing all
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length-of-stay times (in days) that occurred after the base-
line time point. For descriptive purposes, health service
utilisation was divided by time from baseline to death for
each participant to give the proportion of time spent as an
in-patient.
Data analysis
Demographic data of subjects who were included in this
sub-study and those who were not were compared by chi-
square test for categorical data or Mann-Whitney U-test for
continuous and ordinal data.
Analysis of service utilisation was performed using gen-
eralised linear models, with a gamma error distribution and
logarithmic link function. The dependent variable was num-
ber of days spent as an in-patient; in order to remove the
influence of survival time, the logarithm of time from baseline
to death was included as an offset. Kaplan Meier survival
curves were compared using a logrank test. Analyses were
conducted using the software package Stata version 10 (Stata
Corporation, College Station, TX 2007).
Results
Participants
Participants in the RCT did not differ by age, gender,
marital status, or level of education from the whole popula-
tion referred to the palliative care service during the same
period (data not shown), but didmore commonly have cancer
(RCT cohort 91% vs. whole service 85%), and lived longer
from the time of referral to palliative care (median 87 days;
range 1–833), compared with the whole service (median 48
days; range 0–1642). This longer survival is consistent with
the exclusion of patients expected to die within 48 hours of
enrolment, which was used as a means of excluding partici-
pants from the whole cohort study.
For the RCT (from which this sub-study population was
derived), 461 people were enrolled (50% males) with an av-
erage age of 71 years (SD 12). Two hundred and eighty two
participants were married or in a de facto relationship. Ninety
per cent lived in their own home, and 91% had cancer as their
life-limiting illness (Table 1). Baseline entry to the main study
was a mean 107 103 days (median 93; range 11–752) days
before death.
For this sub-study of the RCT population (n¼ 112), the
median Australian-modified Karnofsky Performance Status
scale was 60. The sub-study participants were similar to the
whole cohort, apart from all having a diagnosis of cancer
(as a specific inclusion criterion), having a higher AKPS
(value; p< 0.001) at referral and higher percentage of people
in the stable phase (p¼ 0.006) (62) consistent with better
performance status. The 9% with non-cancer life limiting
illness excluded in this substudy had predominately cardio-
respiratory disease.
Participant flow (using CONSORT criteria) of participants
for the larger RCT is in Fig. 1.
Participant characteristics in this sub-study
Baseline entry to the sub-study was a mean 62 81 days
(median 37, range 1–588) days before death (survival). The
mean time from last assessment until death was 23 days (SD
23 days; median 16 days; range 1–241 days), and the assess-
ment before this was a mean of 29 days earlier (SD 22; median
Table 1. Baseline Demographic and Clinical Characteristics for All Participants and Sub-Study
Participants on Referral to a Randomised Controlled Trial on Palliative Care Service Intervention
Characteristic
n¼ 434
(all participants)
n¼ 322
(not in
sub-study)
n¼ 112
(sub-study
participants)
p value
(two previous
columns)
Age Mean (SD) 71 (12) 71 (12) 72 (12) 0.22
Gender Male 216 (50%) 162 (50%) 54 (48%) 0.70
Marital status Married/De facto 264 (63%) 191 (61%) 73 (66%) 0.36
Widowed 98 (23%) 71 (23%) 27 (25%)
Divorced/Separated 45 (11%) 39 (13%) 6 (5%)
Never Married 15 (4%) 11 (4%) 4 (4%)
Educational level Didn’t complete high school
Completed high school 75 (20%) 58 (21%) 17 (17%) 0.45
Folstein Mini-mental
status exam (20)
Mean (SD) 28.8 (2.2) 28.7 (2.3) 29.0 (1.9) 0.12
Caregiver status Has caregiver 350 (93%) 259 (93%) 91 (95%) 0.45
No caregiver
Accommodation Private residence 387 (91%) 285 (90%) 102 (94%) 0.26
Aged care facility 25 (6%) 20 (6%) 5 (5%)
Hospital 13 (3%) 12 (4%) 1 (1%)
Living arrangement Lived alone 88 (23%) 70 (24%) 18 (19%) 0.56
Lived with spouse/Partner only 234 (61%) 173 (60%) 61 (66%)
Other person in household 61 (16%) 47 (16%) 14 (15%)
Performance status
(AKPS) (21)
Mean (SD) 64.8 (13.9) 63.4 (14.2) 69.2 (12.2) <0.001
Median (range) 70 (20–90) 60 (20–90) 70 (50–90)
AKPS <70% 215 (50%) 174 (54%) 41 (37%)
Phase of palliative care (62) Stable 217 (58%) 143 (54%) 74 (69%) 0.006
McGill Quality of life (23) Mean (SD) 6.1 (2.0) 6.0 (2.0) 6.3 (1.9) 0.17
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25). The mean length of follow-up after first assessment was
109 days (SD 124, range 1–159). The mean number of study
assessments between referral and deathwas 4.8 (median 3, SD
4.18, range 1 – 24) per participant.
Baseline AKPS and total anti-cholinergic score
at first visit AKPS< 60
The distribution of AKPS at the initial assessment (enrol-
ment in study) and anti-cholinergic score at the baseline time
point for this sub-study (defined as the first visit at which
AKPS score was below 60) are shown in Table 2.
Association between health service utilisation
(proportion of time as inpatient) and total
anti-cholinergic scores
Patients spent a mean of 22% (range 0–100%) of their time
as an inpatient. The distribution of total length of stay in Fig. 2.
Analysis using an unadjusted log-gamma model (scaled for
survival time) did not show a significant association between
total anticholinergic score and time spent as an inpatient
(p¼ 0.94) (Fig. 3).
Survival times
The mean survival time for the 112 participants was 8.9
weeks (SD 11.6, median 5.3, range 0.2 – 84.4).
Association of total anti-cholinergic
score with survival
Figure 4 presents a Kaplan-Meier plot showing survival for
the 3 categories of total anti-cholinergic scores. A log-rank test
demonstrated there was no evidence that survival differed
between the 3 groups. The median survival times were ap-
proximately 5 weeks in each group.
Discussion
In this study, no association has been demonstrated be-
tween anti-cholinergic load and changes in survival or health
service utilisation in a population referred to a specialist pal-
liative. It has been previously demonstrated in the setting of a
life limiting illness that the total medication load increases as
death approaches, with the addition of symptom-specific
medication.10 The biggest contributor to anti-cholinergic
scores in a population with advanced cancer is from symp-
tom-specific medications.7 Prior work has shown that anti-
cholinergic load is associated with impaired function,
impaired concentration and dry mouth in this population.7
Referred to the specialist palliative care service (n=2,261) 
Assessed for eligibility (n=1,948) 
Excluded (n=1,487): 
Lived outside of regional care area 
or death expected within 48 hours of 
referral (n=403) 
No pain in preceding three months or 
unable to provide consent (n=7) 
Patient declined participation 
(n=1,038) 
General Practitioner declined 
participation (n=39) (n=461 patient participants with 228 GP 
participants in 105 GP practices 
Known date of death 
n = 304 
Cancer diagnosis, AKPS score at the initial 
assessment of 60 or greater, and a subsequent 
AKPS score of less than 60. 
n = 112 
FIG. 1. Patient flow for all participants and sub-study participants on referral to a randomised controlled trial on palliative
care service intervention.
Table 2. Baseline Total Anti-Cholinergic Score
and Australian-Modified Karnofsky Performance
Status (AKPS) at First Visit Where AKPS was
Less Than 60 in 112 Participants
Score n Percentage (%)
AKPS 10 5 4.5
20 8 7.1
30 9 8.0
40 16 14.3
50 74 66.1
Total anti-cholinergic score 0–2 32 28.6
3–5 47 42.0
6–9 33 29.5
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This current analysis has not demonstrated an association
with anti-cholinergic load and survival or time as an inpatient.
What other data do these findings
support or refute?
Anti-cholinergic medications have been associated with
risk of falls, reduced functional status, and impaired motor
performance, however this is the context of ambulatory pa-
tients in the community over the age of 65.1–6 In a study of
moderately to severely disabled women aged 65 or over and
residing in the community (n¼ 932), anti-cholinergic drug
burden was independently associated with greater difficulty
in several measures of physical function, after adjustment for
age, education and co-morbidities.5 Another study of well
functioning community-dwelling elderly (n¼ 3075) showed
medications with anti-cholinergic effects were associatedwith
poorer physical and cognitive performance after adjusting for
socio-demographic factors and co-morbidities.4
There is also a link with poor cognitive outcomes, espe-
cially in the group with existing cognitive impairment.4,5,26–32
Anti-cholinergic medications can precipitate delirium and
intensify pre-existing delirium.8,25,33–40 An episode of delir-
ium is linked to significant morbidity and mortality, and is
associated with increased length of hospital stay, in-
stitutionalisation, irreversible functional and cognitive de-
cline, and mortality in the elderly.41–49
The prevalence of potentially high risk medication pre-
scribing (considering medications more broadly than just
those with anti-cholinergic effects) in the infirm (especially
the elderly) is high though some improvements have been
seen more recently.50,51 Studies looking at high risk medi-
cations in the elderly in acute care, residential aged care or
community settings (most often classified by Beers’ crite-
ria) have shown contradictory outcomes, with some
showing poor outcomes (increased hospitalisation, in-
creased length of stay, adverse drug reactions, risk of in-
stitutionalisation, mortality) where as others have not
demonstrated this.15–17,52–55
Prescribing patterns and outcomes in palliative care have
been less well described. In the palliative care population in-
creasing total anti-cholinergic load was associated with de-
creased functional status, after adjustment for time from
death; with contribution from symptom-specific medication
to anti-cholinergic load highest in the group with lowest
performance status.7 The population of people with advanced
cancer may differ to aged care populations most notably in
age (one third of the this population is under 65), more
marked cachexia (although levels of sarcopaenia may be
similar) and may not be as susceptible to long term treat-
ment related effects. Similiarities include polypharmacy, co-
morbidities and progressive functional impairment.
Strengths
By anchoring the sub-study population using prospectively
collected data for the time atwhich a predetermined threshold
of functional status was reached in order to define inclusion,
this sub-study allows the analysis of survival in a palliative
population despite widely varying times before death at
which referral to the specialist service occurs. By doing this,
Kaplan Meier curves can be generated in a population with
advanced disease. This is an important evolution in analysis
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FIG. 3. Association between Health Service Utilisation
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moving away from death as the only anchor point to stan-
dardise in palliative care analyses that can be used in pallia-
tive care studies. Such a process can be employed with
different thresholds of functional status on any prospectively
collected data.
Limitations—sample
Not everyone with life-limiting cancer is referred to a spe-
cialist palliative care service and, in general, people with more
complex needs are the people referred.56 Given that people
with prevalent delirium at enrolment to the larger RCT were
excluded from participation and that at least a sub-set of these
people would have developed delirium as a consequence of a
high anti-cholinergic load, it is likely that the current sub-
study will underestimate the consequences of raised anti-
cholinergic load. The requirement for pain to be present in
preceding three months also may alter anti-cholinergic load
due to prevalence of analgesic medication use.
People with cognitive impairment (who are also more at
risk of the consequences of raised anti-cholinergic load) are
not represented in the data. Both exclusions will have po-
tentially increased the survival and decreased the health
service utilisation (number of admissions, length of those
admissions) in this sub-study.
Incident delirium following a previously resolved delirium
occurs in up to 30% of people with advanced cancer. Re-
solution of the second episode of delirium is less likely and
has poorer outcomes; including increased mortality.57,58
This pilot sub-study had a relatively small sample size and
hence is exploratory in nature. It is not adequately powered to
detect differences in health service utilisation or survival, but
of note, the trends seen make it unlikely that any difference
found in a much larger study is likely to be clinically signifi-
cant.
The choice of AKPS as the threshold for the entry to the sub-
study was not entirely arbitrary. This choice needed to bal-
ance the number of people who would be eligible across the
disease trajectory (a very lowAKPS) with the longest possible
time for follow-up after entry to the study (a high AKPS). As
such, crossing the threshold of 60 was chosen as the com-
promise between these two extremes. The inclusion of only
112 out of 434 participants suggests that almost three out of
four people have significant functional impairment at the time
of referral to specialist palliative care.
Limitations—measures/data
Medications used intermittently were not included. Such
medications may contribute to side-effects experienced from
an acutely increased anti-cholinergic load. Only baseline
medications were used for total anti-cholinergic load and
this will underestimate the documented increase in anti-
cholinergic load as symptom controlmedications are added in.
Several methods of calculating anti-cholinergic drug bur-
den have been suggested, including calculating anti-cholinergic
burden score.59 The most comprehensive method currently
available is the Clinician Rated Anti-cholinergic Scale – modi-
fied version24,25 which gives medications one of four ratings:
Level 0 - no known anti-cholinergic properties;
Level 1 - potentially anti-cholinergic as demonstrated by
receptor binding studies;
Level 2 - clinically significant anti-cholinergic effects are
sometimes seen, usually at excessive doses; and
Level 3 - marked anti-cholinergic effects.
This allows calculation of a total anti-cholinergic score at
each time point for each participant.24,25 This classification
was developed using reported anti-cholinergic effects in the
literature, available laboratory data, and ratings of 3 inde-
pendent geriatric psychiatrists.25 The benefits of using the
Clinician Rated Anti-cholinergic Scale – modified version24,25
is that is characterizes medications based on anti-cholinergic
potency, and includes a broader list than just those most fre-
quently recognized as having anti-cholinergic effects, Its
limitations include lack of dose weighting, assumption of
anti-cholinergic effects being additive (not synergistic) and
linear (that is, one medication with score of 3 is equivalent to
three medications each with score of 1).60 A more sophisti-
cated measure which accounts for dose, frequency and du-
ration of use may be needed to understand the totality of
adverse outcomes attributable to anti-cholinergic load from
medications. A gold standard that would be difficult to
achieve would be to measure serum levels of anti-cholinergic
activity longitudinally in this population.
Adjustment for other prognostic factors which indepen-
dently predict survival in advanced cancer was also not per-
formed but will be important in prospective work. These
include presence of dyspnoea, anorexia and delirium, clini-
cians’ predictions of survival, total white cell count and the
proportion of lymphocytes in the total white cell count.61
Future directions: Practice and policy
Given that it is assumed that the cumulative anti-cholinergic
load could be a predictor of toxicity in people with ad-
vanced cancer, the previously demonstrated associations
between raised anti-cholinergic scores, impaired function
and adverse symptoms warrants every effort to reduce anti-
cholinergic load by medication substitution (for a medica-
tion with no or lesser anti-cholinergic load) or deletion of
medications no longer required for managing co-morbid
conditions that are now inactive. A lack of impact on
survival is in this sub-study and is consistent with some
studies in the aged care populations, despite other studies
showing a relationship between medication burden and
mortality.15–17, 52–55
Future direction: Research
Future research needs to prospectively follow a population
of people with advanced cancer, including those with prior
cognitive impairment and those with both prevalent and inci-
dent delirium to further delineate effects of anti-cholinergic load.
Models of prognosis anchored at performance status may also
providemore helpfulways of estimating survival prospectively,
with the ability to raise the threshold for entry into a subsequent
study to AKPS 70 or 80 in order to increase the likelihood of
detecting events over a longer period of observation.
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